Literature DB >> 32882042

Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations.

Myron S Cohen1, Raphael J Landovitz2.   

Abstract

Entities:  

Keywords:  CAB LA; HIV; MSM; PrEP; TDF/FTC; cabotegravir; combination prevention; long-acting

Mesh：

Substances：

Year:  2021        PMID： 32882042      PMCID： PMC7781443          DOI： 10.1093/infdis/jiaa555

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  14 in total

1.  The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men.

Authors:  Preeti Pathela; Sarah L Braunstein; Susan Blank; Colin Shepard; Julia A Schillinger
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

Review 2.  Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.

Authors:  Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-19       Impact factor: 2.205

Review 3.  Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.

Authors:  Lara Esteves Coelho; Thiago Silva Torres; Valdiléa Gonçalves Veloso; Raphael J Landovitz; Beatriz Grinsztejn
Journal:  Lancet HIV       Date:  2019-09-23       Impact factor: 12.767

4.  Ending the HIV Epidemic: A Plan for the United States.

Authors:  Anthony S Fauci; Robert R Redfield; George Sigounas; Michael D Weahkee; Brett P Giroir
Journal:  JAMA       Date:  2019-03-05       Impact factor: 56.272

5.  Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

Authors:  Chloe Orkin; Keikawus Arasteh; M Górgolas Hernández-Mora; Vadim Pokrovsky; Edgar T Overton; Pierre-Marie Girard; Shinichi Oka; Sharon Walmsley; Chris Bettacchi; Cynthia Brinson; Patrick Philibert; Johan Lombaard; Marty St Clair; Herta Crauwels; Susan L Ford; Parul Patel; Vasiliki Chounta; Ronald D'Amico; Simon Vanveggel; David Dorey; Amy Cutrell; Sandy Griffith; David A Margolis; Peter E Williams; Wim Parys; Kimberly Y Smith; William R Spreen
Journal:  N Engl J Med       Date:  2020-03-04       Impact factor: 91.245

6.  The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Authors:  Aaron J Siegler; Farah Mouhanna; Robertino Mera Giler; Kevin Weiss; Elizabeth Pembleton; Jodie Guest; Jeb Jones; Amanda Castel; Howa Yeung; Michael Kramer; Scott McCallister; Patrick S Sullivan
Journal:  Ann Epidemiol       Date:  2018-06-15       Impact factor: 3.797

7.  Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.

Authors:  Brandon D L Marshall; William C Goedel; Maximilian R F King; Alyson Singleton; David P Durham; Philip A Chan; Jeffrey P Townsend; Alison P Galvani
Journal:  Lancet HIV       Date:  2018-06-13       Impact factor: 12.767

8.  Modeling an integrated HIV prevention and care continuum to achieve the Ending the HIV Epidemic goals.

Authors:  Samuel M Jenness; Jordan A Johnson; Karen W Hoover; Dawn K Smith; Kevin P Delaney
Journal:  AIDS       Date:  2020-11-15       Impact factor: 4.632

9.  Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.

Authors:  Rochelle P Walensky; Margo M Jacobsen; Linda-Gail Bekker; Robert A Parker; Robin Wood; Stephen C Resch; N Kaye Horstman; Kenneth A Freedberg; A David Paltiel
Journal:  J Infect Dis       Date:  2015-12-17       Impact factor: 5.226

10.  Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention.

Authors:  Robert L Glaubius; Urvi M Parikh; Greg Hood; Kerri J Penrose; Eran Bendavid; John W Mellors; Ume L Abbas
Journal:  Open Forum Infect Dis       Date:  2016-06-16       Impact factor: 4.423
View more
  1 in total

Review 1.  Promises and challenges: cabotegravir for preexposure prophylaxis.

Authors:  Matthew A Spinelli; Beatriz Grinsztejn; Raphael J Landovitz
Journal:  Curr Opin HIV AIDS       Date:  2022-03-04       Impact factor: 4.061
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.